Loteprednol Etabonate
FDA-approved product (suspension/drops, ophthalmic), marketed as Alrex, Eysuvis, Inveltys and 3 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Allergic conjunctivitis
- Anterior uveitis
- Dry eye syndrome
- Eye inflammation
- Inflammation
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli39.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae23.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Loteprednol Etabonate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Ozanimod HydrochlorideExisting use: Multiple sclerosis, Relapsing-remitting multiple sclerosis, Ulcerative colitis66.8% AI-predicted activityagainst MRSA7 registered studies
- Micafungin SodiumExisting use: Candidiasis66.8% AI-predicted activityagainst MRSA50+ registered studies
- AbemaciclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more66.4% AI-predicted activityagainst MRSA50+ registered studies
- Lazertinib MesylateExisting use: Non-small cell lung carcinoma66.1% AI-predicted activityagainst MRSANo documented evidence found
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia65.8% AI-predicted activityagainst MRSA41 registered studies
- VemurafenibExisting use: Cancer, Cutaneous melanoma, Melanoma and 2 more65.8% AI-predicted activityagainst MRSA50+ registered studies
- Caspofungin AcetateExisting use: Aspergillosis, Candidemia, Candidiasis and 1 more65.5% AI-predicted activityagainst MRSA50+ registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm65.5% AI-predicted activityagainst MRSA50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more65.4% AI-predicted activityagainst MRSA5 registered studies
- SirolimusExisting use: Adenoma sebaceum, Angiofibroma, Cancer and 5 more65.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
NCT00645671 · start 2008-03
Registered record
- Registry ID
- NCT00645671
- Conditions
- Ocular Inflammation
- Interventions
- 0.5% Loteprednol Etabonate Ophthalmic Ointment; Vehicle of Loteprednol Etabonate Ophthalmic Ointment
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-03
- Completion
- 2009-03
- Enrolment
- 400
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOcular InflammationIntervention0.5% Loteprednol Etabonate Ophthalmic Ointment; Vehicle of Loteprednol Etabonate Ophthalmic OintmentPhasePhase 3Registry statusCompletedZylet vs TobraDex in Blepharokeratoconjunctivitis
NCT00447577 · start 2007-01
Registered record
- Registry ID
- NCT00447577
- Conditions
- Blepharokeratoconjunctivitis
- Interventions
- Loteprednol etabonate and tobramycin ophthalmic suspension; Tobramycin and dexamethasone ophthalmic suspension
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2007-01
- Completion
- 2007-06
- Enrolment
- 276
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBlepharokeratoconjunctivitisInterventionLoteprednol etabonate and tobramycin ophthalmic suspension; Tobramycin and dexamethasone ophthalmic suspensionPhasePhase 4Registry statusCompletedMulticenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis
NCT00407043 · start 2006-11
Registered record
- Registry ID
- NCT00407043
- Conditions
- Dry Eye Disease; Keratoconjunctivitis Sicca
- Interventions
- Lotemax; Restasis
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-11
- Completion
- 2007-09
- Enrolment
- 5
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry Eye Disease; Keratoconjunctivitis SiccaInterventionLotemax; RestasisPhasePhase 4Registry statusCompletedIntraocular Pressure With Loteprednol and Dexamethasone
NCT00781300 · start 2006-03
Registered record
- Registry ID
- NCT00781300
- Conditions
- Glaucoma, Open-Angle; Ocular Hypertension
- Interventions
- Loteprednol Etabonate 0.5%; Dexamethasone 0.1%
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-03
- Completion
- 2007-02
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma, Open-Angle; Ocular HypertensionInterventionLoteprednol Etabonate 0.5%; Dexamethasone 0.1%PhasePhase 4Registry statusCompletedComparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation
NCT00366691 · start 2006-02
Registered record
- Registry ID
- NCT00366691
- Conditions
- Cataract Extraction
- Interventions
- Acular LS; Lotemax
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2006-02
- Completion
- 2007-09
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCataract ExtractionInterventionAcular LS; LotemaxPhasePhase 4Registry statusCompleted